By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday an increase in its grant revenues for the fourth quarter and full-year 2010, and a $140.2 million loss for the year as it prepares for the commercial launch of its PacBio RS system.

The Menlo Park, Calif.-based firm reported fourth-quarter revenues of $280,000, up from $220,000 for the fourth quarter of 2009. All of its Q4 and FY 2010 revenues are from government grants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.